Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DYN Dyne Therapeutics	$12.61 +3.2%	$10.27	$6.36 ▼ $46.81	$1.79B	1.08	2.62 million shs	1.49 million shs
IMCR Immunocore	$33.04 +1.1%	$33.33	$23.15 ▼ $39.33	$1.67B	0.77	337,084 shs	173,390 shs
SPRY ARS Pharmaceuticals	$13.63 -8.3%	$16.84	$10.00 ▼ $18.90	$1.36B	0.9	1.56 million shs	2.20 million shs
TECX Tectonic Therapeutic	$25.83 +1.7%	$21.84	$13.70 ▼ $61.07	$484.03M	3.27	264,984 shs	203,025 shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DYN Dyne Therapeutics	+2.09%	-2.24%	+32.68%	+4.53%	-74.02%
IMCR Immunocore	+0.55%	-1.18%	-12.06%	+4.85%	-10.60%
SPRY ARS Pharmaceuticals	+1.85%	+2.76%	-15.46%	-0.73%	+10.97%
TECX Tectonic Therapeutic	+5.48%	+3.80%	+14.31%	+17.32%	+56.31%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DYN Dyne Therapeutics	3.2983 of 5 stars	4.5	1.0	2.0	4.2	0.0
IMCR Immunocore	1.851 of 5 stars	3.3	1.0	2.3	2.5	0.0
SPRY ARS Pharmaceuticals	2.7275 of 5 stars	3.6	0.0	2.3	4.2	0.6
TECX Tectonic Therapeutic	2.73 of 5 stars	3.6	0.0	3.2	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DYN Dyne Therapeutics	3.00	Buy	$33.80	168.15% Upside
IMCR Immunocore	2.50	Moderate Buy	$58.00	75.54% Upside
SPRY ARS Pharmaceuticals	3.17	Buy	$31.00	127.37% Upside
TECX Tectonic Therapeutic	3.17	Buy	$80.33	211.07% Upside

Current Analyst Ratings Breakdown

Latest TECX, DYN, IMCR, and SPRY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/6/2025	DYN Dyne Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$34.00 ➝ $13.00
7/31/2025	DYN Dyne Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$66.00 ➝ $36.00
7/29/2025	DYN Dyne Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$25.00 ➝ $23.00
7/29/2025	DYN Dyne Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$37.00 ➝ $31.00
7/29/2025	DYN Dyne Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$50.00 ➝ $38.00
7/21/2025	TECX Tectonic Therapeutic	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$64.00
7/15/2025	DYN Dyne Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$10.00 ➝ $9.00
7/11/2025	DYN Dyne Therapeutics	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
6/26/2025	DYN Dyne Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$30.00
6/25/2025	DYN Dyne Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/24/2025	DYN Dyne Therapeutics	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Perform	$13.00

(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	$4.02 per share	N/A
IMCR Immunocore	$310.20M	5.37	N/A	N/A	$7.71 per share	4.29
SPRY ARS Pharmaceuticals	$89.15M	15.11	$0.01 per share	1,724.08	$1.95 per share	6.99
TECX Tectonic Therapeutic	N/A	N/A	N/A	N/A	$15.16 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DYN Dyne Therapeutics	-$317.42M	-$3.86	N/A	N/A	N/A	N/A	-64.12%	-56.75%	N/A
IMCR Immunocore	-$51.09M	-$0.40	N/A	N/A	N/A	-5.70%	-5.40%	-1.93%	11/5/2025 (Estimated)
SPRY ARS Pharmaceuticals	$8M	-$0.49	N/A	N/A	N/A	-42.74%	-21.85%	-15.88%	N/A
TECX Tectonic Therapeutic	-$57.98M	-$4.04	N/A	N/A	N/A	N/A	-30.13%	-28.33%	11/6/2025 (Estimated)

Latest TECX, DYN, IMCR, and SPRY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	SPRY ARS Pharmaceuticals	-$0.41	-$0.46	-$0.05	-$0.46	$12.92 million	$15.72 million
8/7/2025	Q2 2025	IMCR Immunocore	-$0.21	-$0.20	+$0.01	-$0.20	$122.96 million	$130.65 million
8/7/2025	Q2 2025	TECX Tectonic Therapeutic	-$0.98	-$1.07	-$0.09	-$1.07	N/A	N/A
7/28/2025	Q2 2025	DYN Dyne Therapeutics	-$0.99	-$0.97	+$0.02	-$0.97	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	N/A
IMCR Immunocore	N/A	N/A	N/A	N/A	N/A
SPRY ARS Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TECX Tectonic Therapeutic	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DYN Dyne Therapeutics	0.17	16.83	16.83
IMCR Immunocore	1.01	5.89	5.86
SPRY ARS Pharmaceuticals	0.37	6.17	5.98
TECX Tectonic Therapeutic	N/A	25.60	25.60

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DYN Dyne Therapeutics	96.68%
IMCR Immunocore	84.50%
SPRY ARS Pharmaceuticals	68.16%
TECX Tectonic Therapeutic	62.63%

Insider Ownership

Company	Insider Ownership
DYN Dyne Therapeutics	14.14%
IMCR Immunocore	10.40%
SPRY ARS Pharmaceuticals	33.50%
TECX Tectonic Therapeutic	38.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DYN Dyne Therapeutics	100	142.26 million	122.15 million	Optionable
IMCR Immunocore	320	50.39 million	45.15 million	Optionable
SPRY ARS Pharmaceuticals	90	98.83 million	65.72 million	Optionable
TECX Tectonic Therapeutic	120	18.71 million	11.60 million	N/A

TECX, DYN, IMCR, and SPRY Headlines

Recent News About These Companies

15,369 Shares in Tectonic Therapeutic, Inc. $TECX Acquired by Cliffwater LLC

August 20 at 7:57 AM | marketbeat.com

Connor Clark & Lunn Investment Management Ltd. Has $614,000 Stock Position in Tectonic Therapeutic, Inc. $TECX

August 20 at 3:41 AM | marketbeat.com

40,000 Shares in Tectonic Therapeutic, Inc. (NASDAQ:TECX) Bought by Knott David M Jr

August 12, 2025 | marketbeat.com

Tectonic Therapeutic (NASDAQ:TECX) Releases Quarterly Earnings Results, Misses Expectations By $0.09 EPS

August 11, 2025 | marketbeat.com

Tectonic Therapeutic Reports Q2 Financial Results

August 9, 2025 | theglobeandmail.com

Tectonic (TECX) Q2 R&D Soars 142%

August 7, 2025 | fool.com

Tectonic Therapeutic Announces Second Quarter 2025 Financial Results and Recent Business Highlights

August 7, 2025 | manilatimes.netM

Tectonic Therapeutic (TECX) to Release Quarterly Earnings on Wednesday

August 7, 2025 | marketbeat.com

Y Intercept Hong Kong Ltd Makes New $234,000 Investment in Tectonic Therapeutic, Inc. (NASDAQ:TECX)

August 1, 2025 | marketbeat.com

Tectonic Therapeutic, Inc. (NASDAQ:TECX) Receives Average Rating of "Buy" from Analysts

July 28, 2025 | marketbeat.com

Windmill Hill Asset Management Ltd Takes Position in Tectonic Therapeutic, Inc. (NASDAQ:TECX)

July 27, 2025 | marketbeat.com

Wall Street Zen Downgrades Tectonic Therapeutic (NASDAQ:TECX) to Sell

July 26, 2025 | marketbeat.com

Tectonic Therapeutic, Inc. Added to Russell 3000® Index Following Annual Reconstitution - Nasdaq

July 1, 2025 | nasdaq.com

Tectonic Therapeutic joins Russell 3000 index

June 30, 2025 | msn.com

Tectonic Therapeutic, Inc. Added to Russell 3000® Index Following Annual Reconstitution

June 30, 2025 | quiverquant.comQ

Tectonic Therapeutic Joins Russell 3000® Index

June 30, 2025 | globenewswire.com

Raymond James Resumes Coverage of Tectonic Therapeutic (TECX) With an Outperform Rating

June 25, 2025 | msn.com

We Think Tectonic Therapeutic (NASDAQ:TECX) Can Afford To Drive Business Growth

June 15, 2025 | finance.yahoo.com

Tectonic Therapeutics (TECX) Gains Outperform Rating from Raymond James | TECX Stock News

June 10, 2025 | gurufocus.com

LifeSci Capital Initiates Coverage of Tectonic Therapeutic (TECX) with Outperform Recommendation

June 7, 2025 | msn.com

Tectonic Therapeutic Holds 2025 Annual Stockholders Meeting

June 6, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

TECX, DYN, IMCR, and SPRY Company Descriptions

Dyne Therapeutics NASDAQ:DYN

$12.60 +0.39 (+3.15%)

As of 03:35 PM Eastern

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Immunocore NASDAQ:IMCR

$33.04 +0.37 (+1.13%)

As of 03:36 PM Eastern

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

ARS Pharmaceuticals NASDAQ:SPRY

$13.63 -1.24 (-8.31%)

As of 03:36 PM Eastern

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

Tectonic Therapeutic NASDAQ:TECX

$25.82 +0.43 (+1.67%)

As of 03:36 PM Eastern

Tectonic Therapeutic, Inc. engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time